Original Articles
25 March 2025
Vol. 19 No. 1 (2025)
https://doi.org/10.4081/itjm.2025.1823

Cytokine profile in COVID-19 infection: focus on interleukin-13, interleukin-33, and tumor necrosis factor-α as immunological markers

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
COVID-19, cytokines, infection
493
Views
478
Downloads
82
HTML

Authors

Huda Saleem
Department of Biochemistry, Al-Kindy College of Medicine, University of Baghdad, Iraq.
Wafaa Hazim
https://orcid.org/0000-0002-9065-6788
Department of Microbiology, Al-Kindy College of Medicine, University of Baghdad, Iraq.
Batool Mutar Mahdi
batoolmutar@kmc.uobaghdad.edu.iq
https://orcid.org/0000-0001-6637-8936
Human Leukocyte Antigen Research Unit, Al-Kindy College of Medicine, University of Baghdad, Iraq.
Mohammed S. Al-Iedani
https://orcid.org/0000-0003-4750-1788
Al-Kindy College of Medicine, University of Baghdad, Iraq.

COVID-19 is a pandemic disease that has a wide spectrum of symptoms from asymptomatic to severe fatal cases due to hyperactivation of the immune system and secretion of pro-inflammatory cytokines. This study aimed to assess the level and impact of interleukin (IL)-13, IL-33, and tumor necrosis factor (TNF)-α cytokines on immune responses in mild and moderate COVID-19-infected Iraqi patients. A prospective case-control study was conducted from January 2023 to January 2024; it included 80 patients infected with moderate COVID-19 infection who consulted in different private clinics and 40 healthy controls. The serum of both groups was tested for quantification of serum IL-13, IL-33, and TNF-α using the human enzyme-linked immunosorbent assay method. The mean age of the moderate COVID-19 patient group was 43.67±1.85 years, while the mean age of the healthy control group was 34.45±3.12 years with a statistically significant (p=0.0081), but there was no statistically significant difference in IL-13, IL-33, and TNF-α levels between the patients and control groups. This study highlights the importance of age, gender, and body mass index as risk factors associated with COVID-19 infection. There were no significant differences in IL-13, IL-33, and TNF-α levels between moderate COVID-19 patients and healthy controls. The receiver operating characteristic curve analysis of IL-13, IL-33, and TNF-α shows moderate potential (non-significant) as a biomarker for predicting mild and moderate COVID-19. Pearson correlation analysis showed a strong potential correlation between IL-13, IL-33, and TNF-α.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Al-Zwaini IJ. Covid-19 and the conspiracy theories. Al-Kindy College Medical J 2021;17:126-7. DOI: https://doi.org/10.47723/kcmj.v17i3.744
Yousif WI. COVID-19 and alimentary tract: current evidence and recent recommendation. Al-Kindy College Medical J 2021;17:62-72. DOI: https://doi.org/10.47723/kcmj.v17i2.311
Dawood H, Hwayyiz A, Ibrahim I, Abdul Rahman I. The clinical features of COVID-19 in a group of Iraqi patients: a record review. J Fac Med Baghdad 2021;63:8-12. DOI: https://doi.org/10.32007/jfacmedbagdad.6311799
Lucijanić M, Piskač Živković N, Režić T, et al. The performance of the WHO COVID-19 severity classification, COVID-GRAM, VACO Index, 4C Mortality, and CURB-65 prognostic scores in hospitalized COVID-19 patients: data on 4014 patients from a tertiary center registry. Croat Med J 2023;64:13-20. DOI: https://doi.org/10.3325/cmj.2023.64.13
Hussein GF. Role of genetic variants AGT rs699 and ACE2 rs2106809 in increasing the risk and severity of COVID-19 infection in Iraqi patients. Iraqi J Sci 2024;65:1917-28. DOI: https://doi.org/10.24996/ijs.2024.65.4.12
Anka AU, Tahir MI, Abubakar SD. et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol 2021;93:e12998. DOI: https://doi.org/10.1111/sji.12998
Yokota S, Miyamae T, Kuroiwa Y, Nishioka K. Novel coronavirus disease 2019 (COVID-19) and cytokine storms for more effective treatments from an inflammatory pathophysiology. J Clin Med 2021;10:801. DOI: https://doi.org/10.3390/jcm10040801
Darif D, Hammi I, Kihel A, et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog 2021;153:104799. DOI: https://doi.org/10.1016/j.micpath.2021.104799
Donlan AN, Sutherland TE, Marie C, et al. IL-13 is a driver of COVID-19 severity. JCI Insight 2021;6:e150107. DOI: https://doi.org/10.1172/jci.insight.150107
Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 2020;20:95-112. DOI: https://doi.org/10.1038/s41577-019-0215-7
Markovic SS, Jovanovic M, Gajovic N, et al. IL 33 correlates with COVID-19 severity, radiographic and clinical finding. Front Med 2021;8:749569. DOI: https://doi.org/10.3389/fmed.2021.749569
Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 2021;184:149-68.e17. DOI: https://doi.org/10.1016/j.cell.2020.11.025
Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol 2023;64:90-107. DOI: https://doi.org/10.1007/s12016-022-08921-5
Ilardi A, Politi C, Ciarambino T. COVID-19: could sex and age be a risk factor? Minerva Med 2023;114:391-2. DOI: https://doi.org/10.23736/S0026-4806.20.06705-1
Srivastava S, Rathor R, Singh S, et al. Obesity: a risk factor for COVID-19. Adv Exp Med Biol 2021;1352:195-210. DOI: https://doi.org/10.1007/978-3-030-85109-5_12
Breland JY, Wong MS, Steers WN, et al. BMI and risk for severe COVID-19 among veterans health administration patients. Obesity 2021;29:825-8. DOI: https://doi.org/10.1002/oby.23121
Au Yeung SL, Li AM, He B, et al. Association of smoking, lung function and COPD in COVID-19 risk: a two-step Mendelian randomization study. Addiction 2022;117:2027-36. DOI: https://doi.org/10.1111/add.15852
Kamali Z, Vonk JM, Thio CHL, et al. Mendelian randomization cytokine screen reveals IL-13 as causal factor in risk of severe COVID-19. J Infect 2022;85:334-63. DOI: https://doi.org/10.1016/j.jinf.2022.05.024
Gao Y, Cai L, Li L, et al. Emerging effects of IL-33 on COVID-19. Int J Mol Sci 2022;23:13656. DOI: https://doi.org/10.3390/ijms232113656
Ramasamy S, Subbian S. Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clin Microbiol Rev 2021;34:e00299-20. Erratum in: Clin Microbiol Rev 2021;34:e0016321. DOI: https://doi.org/10.1128/CMR.00163-21
Smail SW, Babaei E, Amin K, Abdulahad WH. Serum IL-23, IL-10, and TNF-α predict in-hospital mortality in COVID-19 patients. Front Immunol 2023;14:1145840. DOI: https://doi.org/10.3389/fimmu.2023.1145840
Iskandar A, Mayashinta DK, Sutrisnani CS, et al. Correlation between IL-6and age in covid-19; insight from a cross-sectional analysis in Malang, Indonesia. Baghdad Sci J 2024;21:1506-11. DOI: https://doi.org/10.21123/bsj.2023.9005
Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 2020;75:2829-45. DOI: https://doi.org/10.1111/all.14429

How to Cite



Cytokine profile in COVID-19 infection: focus on interleukin-13, interleukin-33, and tumor necrosis factor-α as immunological markers. (2025). Italian Journal of Medicine, 19(1). https://doi.org/10.4081/itjm.2025.1823
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.